TCT 2010: TAVI Takes Center Stage
Executive Summary
In the interventional cardiology community, 2010 could certainly be considered a breakthrough year for percutaneous heart valve devices. At two major US cardiology conferences: the American College of Cardiology in the spring, and most recently, the Transcatheter Cardiovascular Therapeutics symposium, held in September, impressive results from randomized trials of transcatheter heart valve replacement/repair devices set the venues abuzz and had physicians speculating about possible near-term paradigm shifts in the way heart valve disease will be treated. The big questions now are how long it will take before these devices reach the US market, and exactly how many US patients are likely to be implanted once they are available.
You may also be interested in...
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover transcatheter valve news announced at ACC, Covidien's brain aneurysm device, NMT Medical closing shop, J&J's move to acquire Synthes and VisualSonics in vivo imaging technology for cancer.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover transcatheter valve news announced at ACC, Covidien's brain aneurysm device, NMT Medical closing shop, J&J's move to acquire Synthes and VisualSonics in vivo imaging technology for cancer.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover recent device M&A, Medtronic and Nile Therapeutics' collaboration in heart failure, Neoprobe and Naviscan PET Systems' deal in cancer detection, and Qiagen and Epigenomics AG's collaboration in a blood test for colorectal cancer.